After concerns mounted a decade ago over financial ties between drug makers and doctors, various institutions took steps to limit potentially undue influence over medical research and practice. The federal government created a website where companies are required to report payments. And many academic medical centers and physician practices barred or restricted visits by drug sales reps.
But to what extent have these efforts made a difference?
About the Author Reprints
